Insider Selling: CONMED Co. (CNMD) Director Sells 3,000 Shares of Stock
CONMED Co. (NASDAQ:CNMD) Director Jo Ann Golden sold 3,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $63.90, for a total transaction of $191,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
CONMED Co. (NASDAQ CNMD) opened at $63.21 on Monday. CONMED Co. has a fifty-two week low of $39.74 and a fifty-two week high of $64.99. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.56 and a quick ratio of 1.49. The firm has a market cap of $1,765.70, a P/E ratio of 33.27, a P/E/G ratio of 2.57 and a beta of 0.74.
CONMED (NASDAQ:CNMD) last issued its quarterly earnings results on Wednesday, January 31st. The medical technology company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.04. CONMED had a net margin of 6.97% and a return on equity of 9.15%. The company had revenue of $222.60 million for the quarter, compared to the consensus estimate of $212.17 million. During the same quarter in the prior year, the company earned $0.54 EPS. CONMED’s quarterly revenue was up 9.1% on a year-over-year basis. analysts expect that CONMED Co. will post 2.14 earnings per share for the current year.
Several equities analysts recently commented on CNMD shares. Zacks Investment Research raised shares of CONMED from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. KeyCorp reaffirmed a “hold” rating on shares of CONMED in a research report on Friday, November 3rd. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $46.00 price objective on shares of CONMED in a research report on Friday, November 3rd. BidaskClub lowered shares of CONMED from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of CONMED in a research report on Friday, November 17th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $59.00.
WARNING: “Insider Selling: CONMED Co. (CNMD) Director Sells 3,000 Shares of Stock” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/insider-selling-conmed-co-cnmd-director-sells-3000-shares-of-stock/1845556.html.
CONMED Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.